Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 18/20 | 1.00 |
| ▸ | PLA2G4C | Q9UP65 | 2/20 | 0.54 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22222832 | 1.00 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6SLC6A2SLC6A4 | |
| SCHEMBL29380622 | 1.00 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6SLC6A2SLC6A4 | |
| SCHEMBL29862419 | 1.00 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6SLC6A2SLC6A4 | |
| SCHEMBL16908822 | 1.00 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6SLC6A2SLC6A4 | |
| SCHEMBL19689390 | 1.00 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6SLC6A2SLC6A4 | |
| SCHEMBL1684102 | 1.00 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6SLC6A2SLC6A4 | |
| SCHEMBL22222829 | 1.00 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6SLC6A2SLC6A4 | |
| SCHEMBL22187692 | 1.00 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6SLC6A2SLC6A4 | |
| SCHEMBL22222878 | 0.93 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6 | |
| SCHEMBL3690078 | 0.93 | PLA2G4A (1.00) | PLA2G4APLA2G4CPLA2G6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232031-A1 | INJECTABLE FORMULATIONS FOR INTRA-ARTICULAR OR PERI-ARTICULAR ADMINISTRATION | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | claimed |
| EP-2490689-A2 | INJECTABLE FORMULATIONS FOR INTRA- ARTICULAR OR PERI-ARTICULAR ADMINISTRATION | Panmira Pharmaceuticals, LLC (US) | 2012-08-29 | — | — | EP | claimed |
| WO-2011049979-A2 | INJECTABLE FORMULATIONS FOR INTRA- ARTICULAR OR PERI-ARTICULAR ADMINISTRATION | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | WO | claimed |
| US-11000506-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | OPHIREX, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| US-20170354642-A1 | ENVENOMATION THERAPIES AND RELATED PHARMACEUTICAL COMPOSITIONS, SYSTEMS AND KITS | OPHIREX INC (US) | 2017-12-14 | — | — | US | disclosed |
| US-20120232031-A1 | INJECTABLE FORMULATIONS FOR INTRA-ARTICULAR OR PERI-ARTICULAR ADMINISTRATION | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000506-B2 | Envenomation therapies and related pharmaceutical compositions, systems and kits | PLA2R1, PLA2G12A, ACHE | PLA2G4A 9/4885PLA2G4C 19/4885PLA2G6 28/4885 |
| US-20170354642-A1 | ENVENOMATION THERAPIES AND RELATED PHARMACEUTICAL COMPOSITIONS, SYSTEMS AND KITS | PLA2R1, PLA2G12A, ACHE | PLA2G4A 9/4885PLA2G4C 19/4885PLA2G6 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.